SecBot SecBot

MCRB

Seres Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001609809 Biotech & Drug Discovery
$1.98 −0.11 (−5.26%)
Oct 26 4:00 PM ET · prev $2.09
Market cap
$21.4M
Nano cap
Median target
$17.00
+759% · range $12.00–22.00
Next earnings
Nov 3
in 7 days · EPS est. −$1.00
1 year
−88.5%
from $17.17 · Oct 27
30 days
−43.7%
from $3.52
52-week range
$1.98–28.63
at the low
Avg volume 20D
77.9K
Oct 1 spike 247.3K
Short interest
🔒 Subscribers only
Insider net
−$5.8K
0 buyers · 4 sellers · since Mar 4
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 2 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 3, 2026
Strongest BEARISH Seres Therapeutics' S-3 shelf registration (File No. 333-298309) was declared effective by the SEC on August…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $5.8K.

  • InstitutionsBEARISH

    Q2 2026: 2 added (0 new), 6 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$2.370 → −$1.005 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    48% below its 50-day average. New closing low $1.98 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADANEAR_EXIT11—
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM58,328$460.2K
AMERICAN CENTURY COMPANIES INCTRIM28,313$223.4K
MORGAN STANLEYTRIM12,138$95.8K
SIMPLEX TRADING, LLCADD4,598$36.3K
GROUP ONE TRADING LLCDOUBLED3,714$29.3K
UBS Group AGNEAR_EXIT484$3.8K
BARCLAYS PLCNEAR_EXIT167$1.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +759%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jun 23, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$5.8K
sold · 4 insiders
DateInsiderTypeValue
Aug 17, 2026
DesRosier Thomas
See Remarks
SELL$373.10
Aug 17, 2026
Henn Matthew R
See Remarks
SELL$368.55
Aug 17, 2026
Shaff Eric D.
Director
SELL$1.2K
Aug 17, 2026
Brady Kelly
See Remarks
SELL$291.20
Aug 15, 2026
DesRosier Thomas
See Remarks
EXERCISE133 sh
Aug 15, 2026
DesRosier Thomas
See Remarks
EXERCISE112 sh
Aug 15, 2026
DesRosier Thomas
See Remarks
EXERCISE245 sh
Aug 15, 2026
Shaff Eric D.
Director
EXERCISE390 sh

Earnings setup

Estimates
Nov 3
reports in 7 days
−$1.00
EPS estimate, this quarter
+58%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.00-$1.34–-$0.67+38.5%$6.3M
Next Q-$1.01-$1.37–-$0.66+37.7%$6.4M
Current FY-$3.52-$4.36–-$2.67+53.2%$13.8M
Next FY-$4.95-$7.02–-$2.87+24.8%$273.5K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 15, 2026 Other
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, inc
Aug 24, 2026 SEC
Seres Therapeutics' S-3 shelf registration (File No. 333-298309) was declared effective by the SEC on August 21, 2026…
EFFECT — Impact 5/10
Aug 17, 2026 Insider
DesRosier Thomas sold 82 shares
See Remarks @ $4.55 ($373.10)
Aug 17, 2026 Insider
Henn Matthew R sold 81 shares
See Remarks @ $4.55 ($368.55)
Aug 17, 2026 Insider
Shaff Eric D. sold 263 shares
Director @ $4.55 ($1.2K)
Aug 5, 2026 SEC
Seres Therapeutics reported Q2 2026 results with net income of $4.6M ($0.47 EPS) vs consensus loss of -$2.07, driven…
8-K — Impact 6/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — NEAR_EXIT
11 shares (—)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
MCRB Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 15, 2026
Press release
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving…
Sep 8, 2026
Press release
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live…
Sep 1, 2026
Press release
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today…
Aug 4, 2026
Earnings date
MCRB Q2 2026 Earnings Scheduled — 2026-08-04
Jun 5, 2026
Contract
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones

SecBot reports

9 filings · 3 press releases · 2 bullish · 4 bearish · 1 mixed · 2 neutral
All MCRB filing & press-release reports (12)